Clinical Trials for Uterine Cancer

A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with PIK3CA-mutant unresectable or metastatic solid tumors receive zovegalisib (RLY-2608), a mutant-selective allosteric PI3Kα inhibitor, alone. Combination cohorts primarily enroll patients with previously treated HR-positive, HER2-negative advanced breast cancer for zovegalisib plus fulvestrant, with or without palbociclib, ribociclib, or the selective CDK4 inhibitor atirmociclib; selected triplet cohorts also allow endometrial cancer.

ClinicalTrials.gov ID: NCT05216432

A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This single-arm study enrolls patients with recurrent or advanced solid tumors and ECOG performance status 0–1; expansion cohorts require measurable disease. All participants receive XMT-1660 (emiltatug ledadotin), a B7-H4–targeted antibody–drug conjugate that delivers the microtubule inhibitor auristatin F-HPA.

ClinicalTrials.gov ID: NCT05377996

A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembrolizumab

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced or metastatic solid tumors that progressed after at least 3 months of pembrolizumab, and who have no effective treatment options, receive oral PLN-101095 alone or with continued pembrolizumab. PLN-101095 inhibits αvβ8 and αvβ1 integrins to reduce activation of immunosuppressive TGF-β in the tumor microenvironment.

ClinicalTrials.gov ID: NCT06270706

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination With Pembrolizumab, Cetuximab or FOLFIRI Plus Cetuximab in Patients With Advanced Solid Refractory/Resistant Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic refractory/resistant solid tumors, including selected colorectal, head and neck, lung, breast, renal, and acral melanoma cohorts, receive TTX-080, an investigational HLA-G–blocking antibody, alone or with pembrolizumab, cetuximab, or FOLFIRI plus cetuximab. A colorectal cancer cohort compares FOLFIRI plus cetuximab with or without TTX-080.

ClinicalTrials.gov ID: NCT04485013

Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, unresectable or metastatic HER2-expressing or HER2-amplified solid tumors receive trastuzumab deruxtecan, a HER2-directed antibody–drug conjugate carrying a topoisomerase I inhibitor, plus the oral ATR inhibitor ceralasertib. Expansion cohorts are limited to patients with gastroesophageal or colorectal cancer and a biopsiable lesion.

ClinicalTrials.gov ID: NCT04704661

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic non-CNS solid tumors and a BRCA1/2 or other specified homologous-recombination repair alteration receive the investigational oral PARG inhibitor IDE161 alone after progression on or intolerance to standard therapy. A separate cohort with recurrent or advanced endometrial cancer progressing after anti-PD-1/PD-L1 therapy receives IDE161 plus pembrolizumab.

ClinicalTrials.gov ID: NCT05787587

A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This single-arm study enrolls patients aged 1–21 with recurrent or refractory solid tumors, non-Hodgkin lymphoma, or desmoid tumors, with expansion cohorts for selected tumors and Wnt-pathway aberrations extending eligibility to age 30. Patients receive IV tegavivint on days 1, 8, and 15 of each 28-day cycle; it targets TBL1 to disrupt β-catenin–dependent Wnt signaling.

ClinicalTrials.gov ID: NCT04851119

A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and locally advanced or metastatic solid tumors are eligible for tumor-specific cohorts, including non-MSI-H/non-dMMR colorectal cancer, Wnt-pathway–altered tumors, hepatocellular carcinoma, desmoid tumors, and metastatic castration-resistant prostate cancer. Intravenous FOG-001 (zolucatetide), a β-catenin–binding peptide designed to disrupt β-catenin–TCF signaling, is given alone or with mFOLFOX-6/bevacizumab, nivolumab, or trifluridine/tipiracil/bevacizumab.

ClinicalTrials.gov ID: NCT05919264

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors, including ATM-altered cancers and platinum-resistant ovarian cancer, receive the oral ATR kinase inhibitor ART0380 (alnodesertib) alone or with gemcitabine or irinotecan. The ovarian cancer cohort compares ART0380 plus gemcitabine with gemcitabine alone.

ClinicalTrials.gov ID: NCT04657068

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated advanced solid tumors or lymphoma, including disease-specific cohorts defined by ARID1A mutation or BAP1 loss, receive oral tulmimetostat, an investigational EZH2/EZH1 inhibitor that disrupts PRC2-mediated gene repression. A metastatic castration-resistant prostate cancer cohort receives tulmimetostat with enzalutamide.

ClinicalTrials.gov ID: NCT04104776